IL17A and COVID-19: Research by Liu et al. (2022) and Schmidt (2021) indicates that IL-17 inhibitors do not elevate the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or exacerbate the progression of COVID-19 in psoriasis patients.